ACCOUNT

Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

PGe
NEWSLETTERS
PG STORE
ARCHIVES

CLASSIFIEDS

OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS

CONTACT US
ADVERTISING
CAREER OPPORTUNITIES

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Stoke Therapeutics, Inc.

< Previous 1 2 3 Next >

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

October 17, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

September 21, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics Appoints Ian Smith to its Board of Directors

September 20, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress

September 05, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

August 07, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

August 02, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome

July 25, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome

July 21, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

June 16, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

May 04, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics to Present at the BofA Securities Health Care Conference

May 03, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom

April 25, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome

March 15, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

March 06, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics to Participate at Upcoming March Investor Conferences

February 27, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference

February 07, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023

January 09, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

December 02, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

November 29, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

November 14, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome

November 10, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

August 08, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference

June 01, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

May 10, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002

May 02, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

April 07, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

April 05, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference

February 28, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

Stoke Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 04, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Tickers STOK

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.